Laboratory of Physiopharmacology
Vincent Segers is associate professor at the University of Antwerp and interventional cardiologist at the University Hospital Antwerp, Belgium. He graduated medical school Summa cum laude and started his Ph.D. at the laboratory of Physiology at the University of Antwerp and, thereafter, worked in Boston from 2005‒2010, first as a postdoctoral research fellow at Harvard Medical School (2005–2008)—supported by a postdoctoral fellowship of the Belgian American Educational Foundation (BAEF). At the cardiovascular laboratory of Richard Lee, Vincent worked on multiple projects including a project in which he studied myocyte renewal during normal aging and after myocardial injury using a genetic fate-mapping approach. He also invented new protease-resistant variants of Stromal cell-derived factor-1 (SDF1)—a discovery that resulted in the foundation of a start-up biotechnology company, called Provasculon, in 2008. Vincent managed the activities at Provasculon as Senior Director from 2008–2010; Provasculon was acquired by Mesoblast in 2013.
Between Oct 2010 and June 2015, he completed his cardiology training and training in interventional cardiology. In 2013, Vincent Segers was appointed assistant professor of physiology at the University of Antwerp and started to work on the NRG1/ERBB system together with Gilles De Keulenaer. They are interested in basic and translational science in the field of ventricular and atrial myopathy, and use methods ranging from molecular biology to large-animal models. The goal of their lab is to develop new therapies for common cardiovascular diseases, including heart failure.
Inhibition of heme oxygenase-1 impairs cardiac muscle sensitivity to beta-adrenergic stimulation.
Basic research in cardiology May, 2005 | Pubmed ID: 15630521
Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms.
American journal of physiology. Heart and circulatory physiology Apr, 2006 | Pubmed ID: 16243916
Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk.
The Journal of biological chemistry Jul, 2006 | Pubmed ID: 16698793
Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy.
European journal of heart failure Apr, 2007 | Pubmed ID: 17127094
Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction: pathophysiology and natural history.
Current opinion in cardiology May, 2012 | Pubmed ID: 22327289
Pathophysiology of diastolic dysfunction in chronic heart failure.
Future cardiology Sep, 2013 | Pubmed ID: 24020672
Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction.
European heart journal Aug, 2015 | Pubmed ID: 25911648
Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk.
American journal of physiology. Endocrinology and metabolism Apr, 2016 | Pubmed ID: 26786778
ErbB2 signaling at the crossing between heart failure and cancer.
Basic research in cardiology 11, 2016 | Pubmed ID: 27596216
The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function.
European journal of heart failure 05, 2017 | Pubmed ID: 28105791
Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung.
American journal of physiology. Heart and circulatory physiology Nov, 2017 | Pubmed ID: 28822966
Evidence and Indications for Percutaneous Closure of the Left Atrial Appendage.
Revista espanola de cardiologia (English ed.) 09, 2018 | Pubmed ID: 29653775
Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO.
Frontiers in physiology , 2018 | Pubmed ID: 29695980
Cellular senescence links aging and diabetes in cardiovascular disease.
American journal of physiology. Heart and circulatory physiology 09, 2018 | Pubmed ID: 29750567
Short-Term Angiotensin II Treatment Affects Large Artery Biomechanics and Function in the Absence of Small Artery Alterations in Mice.
Frontiers in physiology , 2018 | Pubmed ID: 29867592
Epigenetic regulation of intercellular communication in the heart.
American journal of physiology. Heart and circulatory physiology 06, 2019 | Pubmed ID: 30951364
Cardiac endothelial cell transcriptome in neonatal, adult, and remodeling hearts.
Physiological genomics 06, 2019 | Pubmed ID: 30978160
Coronary-subclavian steal syndrome, an easily overlooked entity in interventional cardiology.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 09, 2020 | Pubmed ID: 31179616
Combined obesity and psychosocial stress is a worldwide health problem and a paracrine disorder.
EBioMedicine Oct, 2019 | Pubmed ID: 31594755
Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure.
Circulation. Heart failure 10, 2019 | Pubmed ID: 31607147
The role of endothelial miRNAs in myocardial biology and disease.
Journal of molecular and cellular cardiology 01, 2020 | Pubmed ID: 31756323
The role of ErbB4 in cancer.
Cellular oncology (Dordrecht) Jun, 2020 | Pubmed ID: 32219702
INSPIRE: A European training network to foster research and training in cardiovascular safety pharmacology.
Journal of pharmacological and toxicological methods Sep, 2020 | Pubmed ID: 32565326
The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling.
American journal of physiology. Heart and circulatory physiology 08, 2020 | Pubmed ID: 32618511
Autocrine Signaling in Cardiac Remodeling: A Rich Source of Therapeutic Targets.
Journal of the American Heart Association 02, 2021 | Pubmed ID: 33470124
Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency.
American journal of physiology. Heart and circulatory physiology 06, 2021 | Pubmed ID: 33989083
ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy.
Circulation. Heart failure Jul, 2021 | Pubmed ID: 34247489
Michiel R. L. Tubeeckx1,
Steven Laga2,
Christel Jacobs3,
Marina Stroe4,
Steven Van Cruchten4,
Bo Goovaerts1,
Jens Van fraeyenhove1,
Hielko Miljoen5,
Guido R. Y. De Meyer1,
Gilles W. De Keulenaer1,6,
Hein Heidbuchel5,7,
Vincent F. M. Segers1,5
1Laboratory of Physiopharmacology, University of Antwerp,
2Department of Cardiac Surgery, University Hospital Antwerp,
3Department of Animal Welfare, University of Antwerp,
4Comparative Perinatal Development, University of Antwerp,
5Department of Cardiology, University Hospital Antwerp,
6Department of Cardiology, ZNA Middelheim Hospital,
7Research Group Cardiovascular Diseases, GENCOR, University of Antwerp
JoVE Hakkında
Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır